Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study

BMC Endocrine Disorders

Volumn 13, Issue , 2013, Pages

  Gayoso Diz, Pilar ^a,b   Otero González, Alfonso ^c   Rodriguez Alvarez, María X ^a,b   Gude, Francisco ^a,b   García, Fernando ^d   De Francisco, Angel ^e   Quintela, Arturo G ^a,b  

^a Instituto de Salud Carlos III   (Spain)

^b Santiago University Clinical Hospital   (Spain)

^c Nephrology Department   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Cardio metabolic risk; Gender; Insulin resistance; Metabolic syndrome

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOMETABOLIC RISK; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METHODOLOGY; OBSERVATIONAL STUDY; RANDOM SAMPLE; SWEDEN;

EID: 84886742013     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-13-47     Document Type: Article

References (42)

1. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007, 120(Suppl 1):S1-S8.
2. Goodwin P, Ennis M, Bahl M. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009, 114:517-525. 10.1007/s10549-008-0019-0, 18437560.
3. Seriolo B, Ferrone C, Cutolo M. Log term anti-tumor necrosis factor α-treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Reumathol 2008, 35:355-357.
4. Chen J, Wildman RP, Hamm LL, Muntner P, Reynolds K, Whelton PK, He J. Third National Health and Nutrition Examination Survey. Association between inflammation and IR in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004, 27:2960-2965. 10.2337/diacare.27.12.2960, 15562214.
5. Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call for action from the American Diabetes Association and the American Heart Association. Circulation 2006, 113:2943-2946. 10.1161/CIRCULATIONAHA.106.176583, 16801475.
6. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definition and controversies. BMC Med 2011, 9:48. 10.1186/1741-7015-9-48, 3115896, 21542944.
7. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365:1415-1428. 10.1016/S0140-6736(05)66378-7, 15836891.
8. Alberti KJ, Eckel RH, Grundy SM, Zimmet PZ, Cleeman LJ, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a join interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120:1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752. 10.1161/CIRCULATIONAHA.105.169404, 16157765.
10. Bray GA, Bellanger T. Epidemiology, trends and morbidities of obesity and the metabolic syndrome. Endocrine 2006, 29:109-117. 10.1385/ENDO:29:1:109, 16622298.
11. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang Y-H, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M. Global burden of metabolic risk factors of chronic diseases collaborating group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2 · 7 million participants. Lancet 2011, 378:31-40. 10.1016/S0140-6736(11)60679-X, 21705069.
12. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalin AN, Farzadfar F, Riley LM, Ezzati M. Global burden of metabolic risk factors of chronic diseases collaborating group (Body mass index). National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9 · 1 million participants. Lancet 2011, 377:557-567. 10.1016/S0140-6736(10)62037-5, 21295846.
13. Lann D, LeRoith D. Insulin resistance as the underlying cause for the metabolic syndrome. Med Clin North Am 2007, 91:1063-1077. 10.1016/j.mcna.2007.06.012, 17964909.
14. Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J, Bastard JP. How can we measure insulin sensitivity/resistance?. Diabetes Metab 2011, 37:179-188. 10.1016/j.diabet.2011.01.002, 21435930.
15. Hedblad B, Nilsson P, Janzon L, Berglund G. Relation between insulin resistance and carotid intima-media thickness and stenosis in non-diabetic subjects. Results from a cross-sectional study in Malmo, Sweden. Diabet Med 2000, 17:299-307.
16. Summer AE, Cowie CC. Ethnic differences in the ability of triglyceride levels to identify insulin resistance. Atherosclerosis 2008, 196:696-703. 10.1016/j.atherosclerosis.2006.12.018, 17254586.
17. Geloneze B, Repetto EM, Geloneze SR, Tambascia MA, Ermetice MN. The threshold value for insulin resistance (HOMA-IR) in an admixture population. IR in the Brazilian metabolic syndrome study. Diabetes Res Clin Pract 2006, 72:219-220. 10.1016/j.diabres.2005.10.017, 16310881.
18. Esteghamati A, Ashraf H, Esteghamati AR, Meysamie A, Khalizadeh O, Nakhjavani M, Abbasi M. Optimal threshold of homeostasis model assessment for insulin resistance in an Iranian population: the implication of metabolic syndrome to detect insulin resistance. Diabetes Res Clin Pract 2009, 84:279-287. 10.1016/j.diabres.2009.03.005, 19359063.
19. Marques-Vidal P, Mazoyer E, Bongard V, Gourdy P, Ruidavets JB, Drouet L, Ferreries J. Prevalence of insulin resistance syndrome in Southwestern France and its relationship with inflammatory and haemostatic markers. Diabetes Care 2002, 25:1371-1377. 10.2337/diacare.25.8.1371, 12145237.
20. Do HD, Lohsoosthorn V, Jiamjarasrangsi W, Lertmaharit S, Williams MA. Prevalence of insulin resistance and its relationship with cardiovascular disease risk factors among Thai adults over 35 years old. Diabetes Res Clin Pract 2010, 89:303-308. 10.1016/j.diabres.2010.04.013, 2919620, 20466446.
21. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of insulin resistance in metabolic disorders. Diabetes 1995, 47:1643-1649.
22. Nakai Y, Fukushima M, Nakaishi S, Kishimoto H, Seino Y, Nagasaka S, Sakai M, Taniguchi A. The threshold value for insulin resistance on homeostasis model assessment of insulin sensitivity. Diabet Med 2002, 19:346-347. 10.1046/j.1464-5491.2002.00712_3.x, 11943012.
23. Pepe MS. The Statistical Evaluation of Medical Tests for Classification and Prediction 2003, New York: Oxford University Press.
24. Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, Cadarso-Suarez C, García F, De Francisco A. IR index (HOMA-IR) levels in a general adult population: curves percentile by gender and age. The EPIRCE study. Diabetes Res Clin Pract 2011, 94:146-155. 10.1016/j.diabres.2011.07.015, 21824674.
25. Otero A, Gayoso P, García F, De Francisco AL. Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int 2005, 99(Suppl 1):S16-S19.
26. Otero A, De Francisco A, Gayoso P, Garcia F. Prevalence of chronic renal disease in Spain: results of the EPIRCE Study. Nefrologia 2010, 30:78-86.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: IR and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
28. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology task force consensus group. The metabolic syndrome: a new world - wide definition. Lancet 2005, 366:1059-1062. 10.1016/S0140-6736(05)67402-8, 16182882.
29. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702, Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.
30. Rodríguez-Álvarez MX, Roca-Pardiñas J, Cadarso-Suárez C. ROC curve and covariates: extending induced methodology to the non-parametric framework. Stat Comput 2011, 21:483-499.
31. Faraggi D. Adjusting receiver operating characteristic curves and related indices for covariates. The Statistician 2003, 52:179-192.
32. Rodríguez-Álvarez MX, Tahoces PG, Cadarso-Suárez C, Lado MJ. Comparative study of ROC regression techniques. Applications for the computer aided diagnostic system in breast cancer detection. Computational Statistics and Data Analysis 2011, 55:888-902.
33. R Development Core Team. R A Language and Environment for Statistical Computing R Foundation for Statistical Computing, Vienna, Austria http://www.R-project.org, R Development Core Team. R.
34. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, Muller M. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinforma 2011, 7:77.
35. Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, Haghazali M, Asgari F. Optimal cut-off of homeostasis model assessment of IR (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab 2010, 7:26.
36. Bertoni AG, Wong ND, Shea S, Ma S, Liu K, Preethi S, Jacobs DR, Wu C, Saad MF, Szkio M. Insulin resistance, metabolic syndrome and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2007, 30:2951-2956. 10.2337/dc07-1042, 17704348.
37. Montecucco F, Steffens S, Mach F. Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm 2008, 2008:767623. 2442435, 18604303.
38. Miccoli R, Biamchi C, Odoguardi L. Prevalence of the metabolic syndrome among Italian adults according to ATPII definition. Nutr Metab Cardiovasc Dis 2005, 15:250-254. 10.1016/j.numecd.2004.09.002, 16054548.
39. Ascaso JF, Romero P, Real JT, Priego A, Valdecabres C, Carmena R. Insulin resistance quantification by fasting insulin plasma values and HOMA index in a non-diabetic population. Med Clin (Barc) 2001, 117:530-533. 10.1016/S0025-7753(01)72168-9, 11707218.
40. Tomé MA, Botana MA, Cadarso-Suarez C, Rego-Irateta A, Fernandez-Mariño A, Mato JA, Solache I, Perez-Fernandez R. Prevalence of metabolic syndrome in Galicia (NW Spain) on four alternative definitions and association with insulina resistance. J Endocrinol Invest 2009, 32:505-511.
41. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna RC, Muggeo M. Bruneck Study. Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from Bruneck Study. Int J Obesity 2003, 27:1283-1289.
42. Ford ES, Giles WH, Dietz WH. Prevalence of metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359. 10.1001/jama.287.3.356, 11790215.